Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2025 07:00 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
November 06, 2025 07:00 ET | Source: Pow.Bio

Pow.Bio, Bühler, and ATV Technologies Announce Major Advancement in Continuous Biomanufacturing with 3,000-Liter Scale Success

Pow.Bio scaled its ML-driven continuous fermentation platform to 3,000L, tripling protein production and cutting costs at a partner facility in France
November 06, 2025 01:00 ET | Source: Pharming Group N.V.

Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow

Pharming Group reports Q3 2025 results with significant growth in revenue, profit, and cash flow driven by rare disease portfolio performance.
November 05, 2025 15:20 ET | Source: Tevogen Bio Inc

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk...
November 05, 2025 08:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Participate in Upcoming November Investor Conferences

Kailera will participate in several upcoming investor conferences in November: Stifel HC Conf, Jefferies London HC Conf, TD Cowen Obesity Summit
November 05, 2025 07:29 ET | Source: Vera Therapeutics

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Vera Therapeutics today reported its business highlights and financial results for the third quarter ended September 30, 2025
November 05, 2025 02:00 ET | Source: Averoa

AVEROA Receives UK MHRA Approval for XOANACYL®, an Oral Therapy Targeting Key Complications of Chronic Kidney Disease (CKD)

The MHRA (Medicines and Healthcare products Regulatory Agency) granted UK Marketing Authorisation for XOANACYL via the International Recognition Procedure (Route B) recognising its prior EU approval...
November 04, 2025 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in November 2025 Investor Conferences

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
November 04, 2025 16:05 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or...
November 04, 2025 16:01 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 +...